Neumora Q1 net loss $53.5M, cash $147M; navacaprant data on track for Q2 2026

Neumora Therapeutics, Inc.

2026-Q1 EPS reported -$0.30

Net loss of $53.5M for Q1 2026, improved from $68.0M in Q1 2025.
Cash and cash equivalents $147.1M as of March 31, 2026; expected to fund operations into Q3 2027.
KOASTAL-2 and -3 fully enrolled with >400 patients each; joint topline readout expected in Q2 2026.
NMRA-511 Phase 1b showed effect in Alzheimer’s agitation; MAD expansion data in H2 2026, Phase 2 planned Q1 2027.
NMRA-898 Phase 1 data in stable schizophrenia expected H2 2026; NMRA-215 preclinical update also in H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Neumora Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $53.5 million.

Period: the first quarter ended March 31, 2026
Net income: $53.5 million
Result: reported results

Exact text from the filing

compared to $18.8 million for the same period in 2025. The decrease was primarily attributable to lower personnel-related costs. • Net Loss: The Company reported a net loss of $53.5 million for the first quarter of 2026, as compared to $68.0 million for the same period in 2025.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Neumora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-210310

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.